NASDAQ: AARDAardvark Therapeutics Inc Stock
$3.82+0.10 (+2.69%)
Updated Jun 17, 2026
AARD Price
$3.82
Fair Value Price
$2.14
Market Cap
$83.34M
52 Week Low
$3.35
52 Week High
$17.94
P/E
-1.19x
P/B
0.96x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$69.87M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
-$62M
Beta
1.7
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AARD Overview
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AARD's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AARD
Ranked#426 of 463
Ranked#426 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $226.93 | A | |
| $52.44 | A | |
| $16.14 | A |
Be the first to know about important AARD news, forecast changes, insider trades & much more!
AARD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AARD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AARD ($3.82) is overvalued by 78.79% relative to our estimate of its Fair Value price of $2.14 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AARD ($3.82) is not significantly undervalued (78.79%) relative to our estimate of its Fair Value price of $2.14 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AARD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AARD due diligence checks available for Premium users.
Valuation
AARD fair value
Fair Value of AARD stock based on Discounted Cash Flow (DCF)
Price
$3.82
Fair Value
$2.14
Overvalued by
78.79%
AARD ($3.82) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AARD ($3.82) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AARD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AARD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.19x
Industry
14.91x
Market
12.4x
AARD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.96x
Industry
4.94x
AARD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AARD's financial health
Profit margin
Revenue
$0.0
Net Income
-$21.6M
Profit Margin
0%
AARD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$98.6M
Liabilities
$11.6M
Debt to equity
0.13
AARD's short-term assets ($93.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AARD's short-term assets ($93.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AARD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$18.9M
Investing
$34.3M
Financing
$4.0k
AARD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AARD vs Biotech Stocks
Aardvark Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.